EXECUTIVE INSIGHTS
DOMAIN EXPERTS
PLAYERS
PARTICIPANTS
-
MAR 2024
-
EDITION 20
-
TABLES 124
-
REGIONS 30
-
SEGMENTS 7
-
PAGES 898
-
US$ 5600
-
MCP-1835
-
JOIN OUR PANEL
EXECUTIVE ENGAGEMENTS BY TIER
-
CXO
-
VICE PRESIDENT
-
DIRECTOR
-
MANAGER
-
MARKETING
© Copy rights Global Industry Analysts, Inc., USA. www.strategyr.com All Rights Reserved.
OUR EXPERT PANELS
Panelists are carefully chosen based on their domain expertise and market influence.
Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.
WHY PARTICIPATE?
Expertise to the Power of YOU!
- Collaborative Insights - Expand your deep domain insights from participants at competitive companies worldwide while you share your own!
- Global Acumen Alerts - Expand your intelligence on your areas of interest by enabling our “Email Alerts” feature drawing from other influencers’ project participation.
- Enterprise-wide Project Discounts - Discounts start @ 10% and build up as more participants support our ongoing projects in your space.
- Complimentary Copies - We highly recommend collaboration with your team to draw upon their geographical domain expertise. Our platform enables collaborative engagements with 10 peers. When you or any of your team members purchase the report, the entire team will receive complimentary copies with full stack access to our data and updates for one year.
- Annual Digital Subscription to one of the business publications or $100 value gift card - No Purchase Required! The lead participant will receive the digital subscription
- The Economist
- MIT Technology Review
- Harvard Business Review
Note - Offer is limited to one participant per company. Offer may be withdrawn at anytime without notice once our annual maximum participation of leading players is fulfilled. Offer by invitation only, to enterprise executives in from companies featured in the project ranked. If you’ve received our initation, you’re qualified! If not, you may check your eligibility by registering to join our Project Expert Panel. Typically you must be have a Marketing, Strategy, Product Management or Business Development, role as a CXO or VP or Director or Manager directly involved with the P&L of the products or services covered in the report. You must complete all modules in the Primary Research Data Simulator.
MARKETGLASS
BASIC
- Annual Prepaid Subscription
- Single-User
- 10,000 Data Room Credits/Month
- Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
- Use MarketGlassTM Data Templates For Your Own Enterprise Data to Build Bespoke Research Reports.
- My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
PREMIUM
- Annual Prepaid Subscription
- One Research Project With One Complimentary Update/Year
- 10-User License
- 10-User Peer-to-Peer Collaborative Features
- 200 Domain Expert Insights (With Name, Company, and Date)
- 50,000 Data Room Credits
- Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
- Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
- Use Your Own Data and MarketGlassTM Data Room Content.
- My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
- Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges
ENTERPRISE
- Annual Prepaid Subscription
- Four Research Projects With One Complimentary Update/Year
- 25-User License
- 25-User Peer-to-Peer Collaborative Engagements
- 500 Domain Expert Insights (With Name, Company, and Date)
- 150,000 Data Room Credits
- Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
- Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
- Use Your Own Data and MarketGlassTM Data Room Content.
- My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
- Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges
HIGHLIGHTS & REPORT INDEX
Global CNS Therapeutics Market to Reach $199 Billion by 2030
The global market for CNS Therapeutics estimated at US$122 Billion in the year 2023, is expected to reach US$199 Billion by 2030, growing at a CAGR of 6.3% over the period 2023-2030. Neurodegenerative Diseases, one of the segments analyzed in the report, is expected to record 6.8% CAGR and reach US$75.9 Billion by the end of the analysis period. Growth in the Mental Health segment is estimated at 6.1% CAGR for the next 8-year period.
The U.S. Market is Estimated at $49.2 Billion, While China is Forecast to Grow at 9.8% CAGR
The CNS Therapeutics market in the U.S. is estimated at US$49.2 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$19.9 Billion by the year 2030 trailing a CAGR of 9.8% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.8% and 5.6% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 5.4% CAGR.
Introducing Our Exciting New Report Features for 2024
» Full access to influencer engagement stats
» Free access to our digital archives & "MarketGlass" research platform. Our proprietary MarketGlass platform is fully enabled to unlock creativity and market knowledge of domain experts worldwide in a cohesive and collaborative manner. Our state-of-art tools bring world class market perspectives while protecting participants` privacy and identity. Numbers, statistics and market narrative in the report are based on fully curated insights shared by domain experts and influencers in this space.
» Opportunity to engage with interactive questionnaires that come with real-time data simulator tools & bespoke report generation capabilities
» Full client access to peer collaborative and interactive platform for cross-enterprise smart exchange of ideas
» Complimentary report updates for one year
» Competitor coverage with global market shares of major players
» Player market presence analysis (Strong/Active/Niche/Trivial) across multiple geographies
» Access to curated YouTube video transcripts of domain experts/influencer interviews, podcasts, press statements and event keynotes
What to Expect from the Global Economy in 2024
Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.
SELECT PLAYERS
Abbott Laboratories, Inc.; AbbVie, Inc.; Acumen Pharmaceuticals, Inc.; Alexza Pharmaceuticals; A. Menarini Industrie Farmaceutiche Riunite Srl; AC Immune SA; Addex Therapeutics; Ache Laboratorios Farmaceuticos SA; 4D pharma plc; Acadia Pharmaceuticals, Inc.; AB Science SA; ABL Bio, Inc.; AcelRx Pharmaceuticals; Aarti Drugs Ltd.; Abion
SEGMENTS
» Segment (Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, CNS Trauma, Infectious Diseases, CNS Cancer, Other Segments)
GEOGRAPHIES
» World » USA » Canada » Japan » China » Europe » France » Germany » Italy » UK » Spain » Russia » Rest of Europe » Asia-Pacific » Australia » India » South Korea » Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » UAE » Rest of Middle East » Africa
TABLE OF CONTENTS
I. METHODOLOGY |
II. EXECUTIVE SUMMARY |
1. MARKET OVERVIEW |
Central Nervous System (CNS) Therapeutics: A Prelude |
Global Central Nervous System Therapeutic Market Glimmers with Robust Health |
Patent Expiries of Major Drugs Exert Downward Pressure on the Global CNS Market |
Developed Markets to Maintain their Dominance |
Developing Market to Drive the Market Momentum, Asia-Pacific to Exhibit Fastest Growth |
Neurodegenerative Disease & Mental Health: Lifeline Segments of CNS Therapeutics Market |
CNS Cancer Segment to Post Fastest Growth |
Competition |
CNS Therapeutics – Global Key Competitors Percentage Market Share in 2023 (E) |
Competitive Market Presence - Strong/Active/Niche/Trivial for 353 Players Worldwide in 2023 (E) |
Recent Market Activity |
MARKET ANALYSIS BY THERAPEUTIC CATEGORY |
Anti-Epilepsy Market |
Regional Landscape |
Developed Countries Account for a Major Share of Epilepsy Treatment |
Developing Countries Struggle with Low Treatment Rates |
Disease Overview |
EXHIBIT: Epilepsy Incidence by Type (2022E): Percentage Share Breakdown for Idiopathic and Symptomatic Epilepsy |
EXHIBIT: Symptomatic Epilepsy Incidence by Type (2022E): Percentage Share Breakdown of Congenital, Degenerative, Infective, Neoplastic, Trauma, and Vascular Epilepsy |
Global Epilepsy Etiology: Percentage Breakdown by Type for 2022E |
Drugs for Epilepsy |
Regional Landscape |
Treatment |
Anti-Epileptic Drugs (AEDs) by Generic Name and Brand Names |
Leading Anti-Epileptic Drugs |
Leading Anti-Epileptic Drugs and Their Mechanism of Action |
Patent Expiries of Major Anti-Epilepsy Drugs |
FDA's New Policy for AED Drugs to Bolster Market Growth |
AAN Updated Guidelines on New AEDs Use for Treating New Onset Epilepsy (2019) |
Select Currently Available Epilepsy Drugs |
Innovative Drugs Needed for Better Treatment Compliance |
Abounding Potential for NCEs |
A New Research Demonstrates Effectiveness of Gluconate in Treating Neonatal Seizures |
FDA Approves Epidiolex (Cannabidiol) - First Drug for Treating Dravet Syndrome and Lennox-Gastaut Syndrome |
Refractory Childhood Epilepsy & Pregnancy Epilepsy - Major Concerns |
Recent Approvals for Childhood Epilepsy |
Review of Anti-Epilepsy Drugs |
Anti-Alzheimer's |
Market Overview |
EXHIBIT: Global Alzheimer's Prevalence by Age Group |
Alzheimer's Phase III Completed Studies |
Alzheimer's Phase III Ongoing Studies |
Treatment for Alzheimer's |
Select Leading Drugs for Alzheimer's Disease by Drug Category |
Patent Expiries of Leading Alzheimer's Drugs |
Alzheimer's Drugs: A Market Plagued with Failures |
Promising Compounds with Silver Lining |
Updated FDA Standards Make Way for Increased Alzheimer’s Drug Testing |
Rising Discontinuation of BACE Programs for Alzheimer's to Dampen Market Growth |
Rising Discontinuation of BACE Programs for Alzheimer's to Dampen Market Growth |
Novel Drug Delivery Method to the Brain Discovered |
Alzheimer's Association Provides Grant to Longeveron |
A Review of Select Anti-Alzheimer's Drugs |
Aricept |
Exelon |
Reminyl |
Ebixa |
Namenda |
A Review of the Alzheimer's disease |
Alzheimer’s Effect on Brain |
Causes for Alzheimer's |
Who Are at Risk? |
Prevalence of Alzheimer’s Disease |
Diagnosis of Alzheimer’s |
Anti-Parkinson's |
Market Overview |
Nourianz, An Add-on Medication for Treating Episodes of Parkinson’s Disease Secures FDA Approval |
Recent Approvals |
Novel Drug and a New Delivery Method for Restoring Brain Cells in People Suffering from PD |
Xadago - Add-On Therapy for Parkinson’s Disease |
NUPLAZID® - The First and the Only Approved Drug for Psychosis related to Parkinson’s disease |
Select Parkinson’s Phase III Completed Studies: As of June 2022 |
Select Parkinson's Ongoing Phase III Studies: As of June 2022 |
Select Anti-Parkinson’s Drugs |
Levodopa |
Dopamine Agonists |
Mirapex |
GSK Discontinues Requip for PD and RSL Treatment |
A Review of the Parkinson’s Disease |
Prevalence |
Symptoms |
Causes |
Diagnosis |
Anti-Depressants |
Market Overview |
EXHIBIT: Anti-Depressant Market: Percentage Share Breakdown by Depressive Disorder Type |
Anti-Depressant Treatment |
Select Antidepressants Drugs |
Zoloft (Sertraline) |
Cymbalta® |
Prozac (Fluoxetine) |
Effexor (Venlafaxine) |
Paxil |
Wellbutrin (Bupropion) |
Select Pipeline Drugs in Phase III for Depressive Disorders: As of June 2022 |
A Review of Depression |
Prevalence of Depression |
Causes of Depression |
Types of Depressive Disorders |
Available Treatment |
Other CNS Disorders (Multiple Sclerosis, Attention Deficit Hyperactivity Disorder (ADHD), and Insomnia) |
Multiple Sclerosis (MS) |
List of Approved Drugs for MS |
Patent Expiration Date/Year of the Major MS Drugs |
New Approvals |
Ocrevus – The First Approved Drug for Primary Progressive Multiple Sclerosis (PPMS) |
Multiple Sclerosis: Pipeline Analysis |
A Review of Multiple Sclerosis (MS) |
Insomnia |
Overview |
List of Approved Drugs for Insomnia |
Select Pipeline Drugs for Insomnia: As of June 2022 |
Zolpidem |
Eszopiclone |
A Review of Insomnia |
Prevalence of Insomnia |
Therapies for Insomnia |
CNS Pain Management |
Market Overview |
Treatment |
Drugs Indicated for Pain Management |
Regional Overview |
Players |
Combination Therapies Gain Prominence |
Key Trends in Chronic Pain Management |
Neuropathic Pain Management: Market with High Potential |
Select Phase III Ongoing Studies for Neuropathic Pain |
Lyrica's Generics Gain FDA Approval |
Migraine Market: A Core Vertical in CNS Pain Management |
Migraine Care: Select Patent Expiries (2013-2015) |
Migraine Completed Phase III Studies |
Migraine Ongoing Phase III Studies |
Select Pain Management Drugs |
Flupirtine |
Lyrica |
Oxycodone |
Nucynta ER |
Metabotropic Glutamate Receptors (mGluRs) |
New Pain Management Drugs |
Novartis Presents New Data for Aimovig |
Reyvow, Eli Lilly's Novel Migraine Drug with the Potential to Lead the Global Migraine Medications Market |
Three New Migraine Drugs Obtain FDA Approval |
Eli Lilly's Emgality Receives FDA Approval |
An Insight into Mental Health Prevalence and Addressal |
EXHIBIT: Global Prevalence of Mental Health Disorders by Type |
Anti-Psychotics |
2. FOCUS ON SELECT PLAYERS |
3. MARKET TRENDS & DRIVERS |
Rising Incidence of Neurodegenerative Conditions |
Burgeoning Global Aging Populace, Longer Life Expectancy to Drive CNS Demand |
EXHIBIT: Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050 |
Increased Spending on Prescription Drugs Bodes Well for the CNS Therapeutics Market |
Rising Healthcare Expenditure to Boost CNS Therapeutics Market |
EXHIBIT: World Healthcare Expenditure (In US$ Trillion) for the Years 2017, 2019, 2021 & 2023 |
EXHIBIT: Per Capita Healthcare Expenditure (in $) by Select Countries for 2018 |
Growing Middle Class Population in Emerging Regions to Spur the Market |
EXHIBIT: Global Middle Class Population (In Million) by Region for the Years 2020, 2025 and 2030 |
EXHIBIT: Global Middle Class Spending (US$ Trillion) by Region for the Years 2020, 2025, 2030 |
Developments in CNS Drug Delivery Technologies Bode Well for the CNS Drugs Market |
Understanding of BBB Cell Biology & Its Positive Impact on Epilepsy Drugs: A Case-in-Point |
Pharma Companies: Seeking New Tools to Offset Pressure on Drug Pipelines |
Awareness Campaigns Launched by Pharma Companies to Benefit the Market… |
Music and Memory Programs Positively Impact Alzheimer’s Disease (AD) and Related Dementia (ADRD) Patients |
New Method to Isolate Active Compounds Related to Alzheimers from Plant Medicines |
Influx of New Products & Strong Pipeline |
CNS Pharmaceuticals Secures FDA Approval for Protocol Amendment to Trial Targeting GBM Treatment |
Central Nervous System Therapeutics: From Bleak to Bright Outlook |
Novel Drug-Delivery Options |
Advances in Drug Discovery Methods for Rare Diseases |
Market Restraint: Complex Nature of R&D |
Ongoing Research on Psychedelics Substances Pave Way for Ensuring Timely Treatment for Various Mental Illnesses |
Advent of Advanced Disease Pathology and Diagnostics Techniques Facilitate Medical Professionals in Diagnosing Mental Illness at an Earlier Stage |
Introduction of Innovative Technologies Fuel Demand for Biological Medicines |
4. GLOBAL MARKET PERSPECTIVE |
World CNS Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030 |
World Recent Past, Current & Future Analysis for CNS Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
World Historic Review for CNS Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Neurodegenerative Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
World Historic Review for Neurodegenerative Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Neurodegenerative Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Mental Health by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
World Historic Review for Mental Health by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Mental Health by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Neurovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
World Historic Review for Neurovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Neurovascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Cns Trauma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
World Historic Review for Cns Trauma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Cns Trauma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Cns Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
World Historic Review for Cns Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Cns Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030 |
World Recent Past, Current & Future Analysis for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
World Historic Review for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
World 16-Year Perspective for Other Segments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030 |
III. MARKET ANALYSIS |
UNITED STATES |
Market Facts & Figures |
Aging Population: A Strong Demographic Driver |
EXHIBIT: North American Elderly Population by Age Group (1975-2050) |
The Largest CNS Therapeutics Market Globally |
Patent Expiries of Leading CNS Drugs in the US |
Focus on Select Markets |
Alzheimer’s Market |
Anti-depressant Drugs |
Usage of Antidepressants Surges in the US |
Anti-Epilepsy Market |
Epilepsy - A Major Concern for the Healthcare Industry |
A Glance at Epilepsy Statistics |
Anti-Epilepsy Drugs |
Epilepsy in Children |
Growing Competition from Generics |
Pain Management Market |
Consumers in the US Seek Different Options for Chronic Pain Management |
Neuropathic Pain Market |
Anti-Psychotic Drugs Market |
Mental Illnesses - Epidemiology |
Facts & Figures |
Popular Antipsychotic Drugs in the US |
Surging Off-label Prescriptions |
Generics Occupy Front Seat |
Rising Antipsychotic Use among Children - A Cause of Concern |
Market Analytics |
USA Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
USA Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
USA 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030 |
CANADA |
CNS Diseases: Facts & Figures |
Canada Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Canada Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Canada 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030 |
JAPAN |
Japan Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Japan Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Japan 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030 |
CHINA |
China: The Primary Market for CNS Drugs in Asia-Pacific |
Select Anti-Schizophrenia Drugs Available in China |
Other Available CNS Drugs in China |
China Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
China Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
China 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030 |
EUROPE |
Market Facts & Figures |
Pain Management Market |
Neuropathic Pain Market Witnesses Foray of Generics |
Anti-Psychotics Market |
Demand for Antipsychotics for Bipolar Disorder Upbeat |
Europe Recent Past, Current & Future Analysis for CNS Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
Europe Historic Review for CNS Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Europe 16-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030 |
Europe Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Europe Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Europe 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030 |
FRANCE |
France Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
France Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
France 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030 |
GERMANY |
Germany Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Germany Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Germany 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030 |
ITALY |
Market Snapshots |
Italy Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Italy Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Italy 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030 |
UNITED KINGDOM |
NICE Recommendations on CNS Therapeutics |
UK Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
UK Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
UK 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030 |
SPAIN |
Spain Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Spain Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Spain 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030 |
RUSSIA |
Russia Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Russia Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Russia 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030 |
REST OF EUROPE |
Rest of Europe Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Rest of Europe Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Rest of Europe 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030 |
ASIA-PACIFIC |
India & China Offer Significant Growth Opportunities |
Growing Antipsychotics Market in Asia |
Asia-Pacific Recent Past, Current & Future Analysis for CNS Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
Asia-Pacific Historic Review for CNS Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Asia-Pacific 16-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030 |
Asia-Pacific Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Asia-Pacific Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Asia-Pacific 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030 |
AUSTRALIA |
Australia Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Australia Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Australia 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030 |
INDIA |
India Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
India Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
India 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030 |
SOUTH KOREA |
South Korea Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
South Korea Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
South Korea 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030 |
REST OF ASIA-PACIFIC |
Rest of Asia-Pacific Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Rest of Asia-Pacific Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Rest of Asia-Pacific 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030 |
LATIN AMERICA |
Latin America Recent Past, Current & Future Analysis for CNS Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
Latin America Historic Review for CNS Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Latin America 16-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030 |
Latin America Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Latin America Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Latin America 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030 |
ARGENTINA |
Argentina Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Argentina Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Argentina 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030 |
BRAZIL |
Brazil Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Brazil Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Brazil 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030 |
MEXICO |
Mexico Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Mexico Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Mexico 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030 |
REST OF LATIN AMERICA |
Rest of Latin America Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Rest of Latin America Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Rest of Latin America 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030 |
MIDDLE EAST |
Middle East Recent Past, Current & Future Analysis for CNS Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR |
Middle East Historic Review for CNS Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Middle East 16-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030 |
Middle East Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Middle East Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Middle East 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030 |
IRAN |
Iran Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Iran Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Iran 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030 |
ISRAEL |
Israel Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Israel Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Israel 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030 |
SAUDI ARABIA |
Saudi Arabia Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Saudi Arabia Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Saudi Arabia 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030 |
UNITED ARAB EMIRATES |
UAE Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
UAE Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
UAE 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030 |
REST OF MIDDLE EAST |
Rest of Middle East Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Rest of Middle East Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Rest of Middle East 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030 |
AFRICA |
Africa Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR |
Africa Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR |
Africa 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030 |
IV. COMPETITION |
(including Divisions/Subsidiaries - 181) |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com
DIFFERENTIATORS
Our research offerings primarily draw upon unique perspectives of participating executives and their experiences in operating and strategy roles. These geo-focused insights enrich our projects .
What we are NOT - Our reports are not editorial exercises of remote analysts’ secondary source fed content that predominantly flood today’s off-the-shelf market report business. (A review of 262 publishers).
WHAT SETS US APART
FULL STACK DATA ACCESS
- Primary Research Cluster Data
- Influencer Engagement Stats
- Evidence of Primary Research
- List of Companies Engaged
- Hundreds of Pages of Research
- Peer Collaborative Interactions
- Enterprise Data Exchanges
- MarketGlassTM Platform Insider
- Geographic Pricing Dynamics
- Competitive Shares by Country
- Brand Curation & Insights
- Domain Expert Pool
Program Transparency: Clients have access to engagement stats of companies and executives. Clients may commission third-party audits of our influencer engagements at their expense.
Primary Research: We have a very successful incentive driven primary research program presenting a rich experience to participating executives. Featured company executives can sign up for a complimentary.
Collaborative Intelligence: Our platform presents a unique features for executives to collaborate with peers across geographies and participate on various product or regional perspectives for a collective unified insider project experience.
Global Brand Intelligence: We present competitive brand intelligence at the company level for players worldwide. Executives from brand owner companies participate to curate each brand for relevance and market presence.
Bespoke Updates: Our peer-to-peer online interactive platform enables client companies to build upon our project data stacks to build bespoke editions for internal sharing and use. Client company can build one complimentary update per year and unlimited updates for additional fee. Bespoke updates are fulfilled within a two-day turnaround.
Enterprise EcoConnect: Discretely bounce off queries to participant pool of executives. We can reach out to our participant pool based on specifics of geographic or domain acumen.
Renowned Support: We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.
Complimentary Updates: Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.
No Fluff: We offer our clients the best CX with clean easy to read content. No verbose fluff. We offer clients full access to the entire stack of hundreds of pages of secondary research feeds used in our project via our online MarketGlass portal.